Last reviewed · How we verify

Fentanyl-TTS

Janssen-Cilag, S.A. · FDA-approved active Small molecule

Fentanyl-TTS is a transdermal patch that delivers the opioid fentanyl through the skin at a controlled rate to provide long-acting pain relief.

Fentanyl-TTS is a transdermal patch that delivers the opioid fentanyl through the skin at a controlled rate to provide long-acting pain relief. Used for Chronic pain in opioid-tolerant patients, Cancer pain, Severe chronic pain requiring opioid therapy.

At a glance

Generic nameFentanyl-TTS
Also known asfentanyl
SponsorJanssen-Cilag, S.A.
Drug classOpioid analgesic
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Fentanyl is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central and peripheral nervous system, inhibiting pain signal transmission and producing analgesia. The transdermal therapeutic system (TTS) formulation allows continuous delivery of fentanyl over 72 hours, maintaining steady-state plasma concentrations and providing sustained pain control without frequent dosing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: